Compass Therapeutics To Present Data On Novel Mechanism Of Action For CTX-10726 At 41st Society For Immunotherapy Of Cancer Annual Meeting
CTX-10726, a PD-1 x VEGF-A bispecific antibody discovered and engineered at Compass, exhibits a unique mechanism of action that has not been previously reported in this class of drugs, characterized by VEGF-A-dependent
Compass is showing off a new kind of medicine at a big doctor meeting. When a company presents new research, watch if doctors seem excited about it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.